All
Review Confirms Safety and Efficacy of Radium-223 in mCRPC
A review of 50 studies confirmed the safety and efficacy of radium-223 for metastatic castration-resistant prostate cancer treatment.
Ruxolitinib Shows Promise in Preventing GVHD in Myelofibrosis
A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing transplant.
Consistent Response, Durability Shown by Axatilimab Regardless of Prior Lines of Therapy in cGVHD
Axatilimab demonstrated consistent response and durability in chronic graft-versus-host disease, regardless of prior treatments, in a phase 1 AGAVE-201 trial analysis.
Vimseltinib Gains FDA Approval in Tenosynovial Giant Cell Tumor
Vimseltinib is now an FDA-approved treatment for patients with tenosynovial giant cell tumor, based on findings from the phase 3 MOTION trial.
Building Trust to Overcome Medical Mistrust in Clinical Trials
Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss how medical mistrust has impacted participation in oncology clinical trials.
Estradiol and Hormone Therapy Show Similar PSA Response in Prostate Cancer
Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen receptor inhibitors in prostate cancer.
Lenvatinib Plus Pembrolizumab Reinforces Long-Term Efficacy in Advanced RCC
Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.
Axatilimab Plus Ruxolitinib/Belumosudil May Yield Benefit in cGVHD
In a retrospective cohort of patients with severe chronic GVHD, combination axatilimab with other GVHD therapies led to clinical benefit.
Defibrotide Does Not to Prevent Sinusoidal Obstruction Syndrome in High-Risk Pediatric HSCT
Defibrotide prophylaxis after HSCT did not reduce sinusoidal obstructive syndrome incidence in high-risk pediatric patients, per retrospective study at 2025 Tandem Meeting.
Zamto-Cel Shows Durable Responses in Relapsed/Refractory DLBCL
Zamtocabtagene autoleucel induced responses, including durable complete responses, in relapsed/refractory diffuse large B-cell lymphoma.
Off-the-Shelf CAR-T Therapy P-BCMA-ALLO1 Shows Strong Activity in R/R Myeloma
The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor activity in patients with relapsed/refractory multiple myeloma.
High PSA Before HIFU Tied to Increased Recurrence, Treatment Failure
High prostate-specific antigen levels before High-Intensity Focused Ultrasound were linked to higher recurrence and treatment failure in intermediate-risk prostate cancer.
Long-Term Outcomes of EBRT and Androgen Deprivation in Prostate Cancer
Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.
CTCm Score Predicts Outcomes in mCRPC Treated With Bavdegalutamide
CTCm from circulating tumor cells correlated with outcomes in mCRPC patients treated with bavdegalutamide in the ARDENT trial.
Radium-223 Re-Treatment Deemed Safe in mCRPC
Radium-223 re-treatment is safe for metastatic castration-resistant prostate cancer, per findings from the 2025 ASCO GU Cancers Symposium.
Olaparib Boosts Survival in BRCA-Mutated mCRPC, PROpel Analysis Shows
Olaparib plus abiraterone improved survival vs placebo in BRCA-mutated metastatic castration-resistant prostate cancer.
Darolutamide Improves Outcomes in mHSPC Regardless of Disease Volume
Darolutamide plus ADT improved outcomes in metastatic hormone-sensitive prostate cancer, regardless of disease volume, in the phase 3 ARANOTE trial.
FDA Fast Tracks CUSP06 in Platinum-Resistant Ovarian Cancer
EBRT Shows 15-Year Survival in Intermediate-Risk Prostate Cancer
External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for intermediate-risk prostate cancer.
Darolutamide Benefits All Ages in Metastatic Prostate Cancer
Darolutamide with ADT and docetaxel benefits both younger and older patients with metastatic hormone-sensitive prostate cancer, per post hoc analysis.
Umbilical Cord Blood Transplant Effective in Patients With Blood Cancer
Unrelated cord blood transplant demonstrated efficacy in patients with blood cancer after microcystic adnexal carcinoma.
Darolutamide Shows Stronger Benefits in Non-Metastatic Prostate Cancer
Darolutamide may offer greater benefits than enzalutamide or apalutamide for Black and White patients with non-metastatic castration-resistant prostate cancer.
Gaps in Genetic Testing and Targeted Therapy for Advanced Prostate Cancer
Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate cancer, stressing need for improvement.
G-CSF Use Maintains Effective Docetaxel Dose in ARASENS Regimen for mHSPC
G-CSF plus docetaxel modification allowed almost all patients with mHSPC to receive an efficacious dose of docetaxel plus darolutamide/ADT.
Adding 177Lu-PSMA-617 to Enzalutamide Improves Survival, QOL in mCRPC
The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic castration-resistant prostate cancer.
NKTR-255 Plus Anti-CD19 CAR T Shows Safety, Efficacy in R/R LBCL
NKTR-255 with CD19 chimeric antigen receptor T-cell therapy improved 6-month complete response rates in relapsed/refractory large B-cell lymphoma.
Anakinra Does Not Reduce CRS or ICANS in LBCL Treated With Liso-cel
Anakinra failed to reduce cytokine release syndrome or immune effector cell–associated neurotoxicity in patients with large B-cell lymphoma receiving liso-cel.
Obe-Cel Linked to Better Outcomes in R/R B-ALL With Low-Risk Scores
Obecabtagene autoleucel improved outcomes in relapsed/refractory B-cell acute lymphoblastic leukemia with low-risk CAR-HEMATOTOX scores in the 1/2 FELIX trial.
Talazoparib Plus Enzalutamide Extends Survival in mCRPC
Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient patients seeing a 14-month gain and 38% lower death risk.
Managing BsAb-Associated AEs in a Community Setting
One concern with bispecific antibody therapies in community settings is managing adverse events, with emerging patterns guiding management strategies.
